Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis

where do we stand?

Alberto Mussetti, Raffaella Greco, Jacopo Peccatori, Paolo Corradini

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Introduction: Post transplant cyclophosphamide (PT/Cy) in association to other immunosuppressive agents or alone has emerged as a promising pharmacological strategy in the setting of allogeneic hematopoietic cell transplant (allo-HCT). Its safety profile and effectiveness in reducing GvHD (acute GvHD incidence comprised between 15 and 30%, chronic GvHD 20–30% in the haploidentical setting) contributed to the spreading of this technique all over the world. Areas covered: This review summarizes the use of PT/Cy in the setting of allo-HCT, both for oncological and non-malignant hematological diseases. Recent studies showed the feasibility of more intense conditioning regimens instead of the original NMAC. The use of peripheral blood stem cells instead of bone marrow as graft source (slightly increase of acute GvHD grade 2 but no differences in survival outcomes) was another significant variation to the original protocol. Later on, PT/Cy alone or in combination with other immunosuppressive agents (ATG, sirolimus, cyclosporine) were tested in the HLA-matched donor setting where lower GvHD rates are reported (acute GvHD grade 3 of 5–10% and chronic GvHD of 10–20%) Expert commentary: The best graft source and type of donor is still ongoing. Moreover, the research of the best pharmacological partner of PT/Cy remains an open question.

Original languageEnglish
Pages (from-to)479-492
Number of pages14
JournalExpert Review of Hematology
Volume10
Issue number5
DOIs
Publication statusPublished - May 4 2017

Fingerprint

Graft vs Host Disease
Cyclophosphamide
Transplants
Immunosuppressive Agents
Pharmacology
Hematologic Diseases
Feasibility Studies
Sirolimus
Cyclosporine
Bone Marrow
Safety
Incidence
Research

Keywords

  • Allogeneic transplant
  • graft-versus-host disease
  • haploidentical
  • matched related donor
  • post-transplant cyclophosphamide

ASJC Scopus subject areas

  • Hematology

Cite this

Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis : where do we stand? / Mussetti, Alberto; Greco, Raffaella; Peccatori, Jacopo; Corradini, Paolo.

In: Expert Review of Hematology, Vol. 10, No. 5, 04.05.2017, p. 479-492.

Research output: Contribution to journalReview article

@article{afaa6de3d5c749a8a91b35e95c6b72f6,
title = "Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis: where do we stand?",
abstract = "Introduction: Post transplant cyclophosphamide (PT/Cy) in association to other immunosuppressive agents or alone has emerged as a promising pharmacological strategy in the setting of allogeneic hematopoietic cell transplant (allo-HCT). Its safety profile and effectiveness in reducing GvHD (acute GvHD incidence comprised between 15 and 30{\%}, chronic GvHD 20–30{\%} in the haploidentical setting) contributed to the spreading of this technique all over the world. Areas covered: This review summarizes the use of PT/Cy in the setting of allo-HCT, both for oncological and non-malignant hematological diseases. Recent studies showed the feasibility of more intense conditioning regimens instead of the original NMAC. The use of peripheral blood stem cells instead of bone marrow as graft source (slightly increase of acute GvHD grade 2 but no differences in survival outcomes) was another significant variation to the original protocol. Later on, PT/Cy alone or in combination with other immunosuppressive agents (ATG, sirolimus, cyclosporine) were tested in the HLA-matched donor setting where lower GvHD rates are reported (acute GvHD grade 3 of 5–10{\%} and chronic GvHD of 10–20{\%}) Expert commentary: The best graft source and type of donor is still ongoing. Moreover, the research of the best pharmacological partner of PT/Cy remains an open question.",
keywords = "Allogeneic transplant, graft-versus-host disease, haploidentical, matched related donor, post-transplant cyclophosphamide",
author = "Alberto Mussetti and Raffaella Greco and Jacopo Peccatori and Paolo Corradini",
year = "2017",
month = "5",
day = "4",
doi = "10.1080/17474086.2017.1318054",
language = "English",
volume = "10",
pages = "479--492",
journal = "Expert Review of Hematology",
issn = "1747-4086",
publisher = "Taylor and Francis Ltd.",
number = "5",

}

TY - JOUR

T1 - Post-transplant cyclophosphamide, a promising anti-graft versus host disease prophylaxis

T2 - where do we stand?

AU - Mussetti, Alberto

AU - Greco, Raffaella

AU - Peccatori, Jacopo

AU - Corradini, Paolo

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Introduction: Post transplant cyclophosphamide (PT/Cy) in association to other immunosuppressive agents or alone has emerged as a promising pharmacological strategy in the setting of allogeneic hematopoietic cell transplant (allo-HCT). Its safety profile and effectiveness in reducing GvHD (acute GvHD incidence comprised between 15 and 30%, chronic GvHD 20–30% in the haploidentical setting) contributed to the spreading of this technique all over the world. Areas covered: This review summarizes the use of PT/Cy in the setting of allo-HCT, both for oncological and non-malignant hematological diseases. Recent studies showed the feasibility of more intense conditioning regimens instead of the original NMAC. The use of peripheral blood stem cells instead of bone marrow as graft source (slightly increase of acute GvHD grade 2 but no differences in survival outcomes) was another significant variation to the original protocol. Later on, PT/Cy alone or in combination with other immunosuppressive agents (ATG, sirolimus, cyclosporine) were tested in the HLA-matched donor setting where lower GvHD rates are reported (acute GvHD grade 3 of 5–10% and chronic GvHD of 10–20%) Expert commentary: The best graft source and type of donor is still ongoing. Moreover, the research of the best pharmacological partner of PT/Cy remains an open question.

AB - Introduction: Post transplant cyclophosphamide (PT/Cy) in association to other immunosuppressive agents or alone has emerged as a promising pharmacological strategy in the setting of allogeneic hematopoietic cell transplant (allo-HCT). Its safety profile and effectiveness in reducing GvHD (acute GvHD incidence comprised between 15 and 30%, chronic GvHD 20–30% in the haploidentical setting) contributed to the spreading of this technique all over the world. Areas covered: This review summarizes the use of PT/Cy in the setting of allo-HCT, both for oncological and non-malignant hematological diseases. Recent studies showed the feasibility of more intense conditioning regimens instead of the original NMAC. The use of peripheral blood stem cells instead of bone marrow as graft source (slightly increase of acute GvHD grade 2 but no differences in survival outcomes) was another significant variation to the original protocol. Later on, PT/Cy alone or in combination with other immunosuppressive agents (ATG, sirolimus, cyclosporine) were tested in the HLA-matched donor setting where lower GvHD rates are reported (acute GvHD grade 3 of 5–10% and chronic GvHD of 10–20%) Expert commentary: The best graft source and type of donor is still ongoing. Moreover, the research of the best pharmacological partner of PT/Cy remains an open question.

KW - Allogeneic transplant

KW - graft-versus-host disease

KW - haploidentical

KW - matched related donor

KW - post-transplant cyclophosphamide

UR - http://www.scopus.com/inward/record.url?scp=85019941818&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019941818&partnerID=8YFLogxK

U2 - 10.1080/17474086.2017.1318054

DO - 10.1080/17474086.2017.1318054

M3 - Review article

VL - 10

SP - 479

EP - 492

JO - Expert Review of Hematology

JF - Expert Review of Hematology

SN - 1747-4086

IS - 5

ER -